HOME >> BIOLOGY >> NEWS
JCI Table of Contents, November 3, 2003

Gene therapy establishes a TRAIL to arthritis treatment

In the November 3 issue of the Journal of Clinical Investigation, John Mountz and colleagues from the University of Alabama at Birmingham describe a gene-modified cell therapy utilizing the TRAIL molecule that successfully limits the incidence and severity of arthritis in a mouse model of collagen-induced arthritis and joint inflammation. The regime represents a therapeutic option for systemic rheumatic diseases.

Mountz and colleagues isolated dendritic cells prepared from either peripheral blood or bone marrow, which were then pulsed with collagen. The DNA of an adenovirus expressing tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) was then introduced into these cells. The design of the adenovirus vector allowed the researchers to "switch on" the expression of TRAIL by these gene-modified dendritic cells at their discretion, by the addition of doxycycline (DOX).

A cascade of immunological events including lymphocyte activation, lymphokine production, and proliferation of synovial cells (which comprise the loose connective tissue lining the joint cavity) is associated with collagen-induced arthritis in mice. Mountz and colleagues found that infusion of collagen-pulsed DOX-inducible TRAIL-expressing dendritic cells into these mice induced the apoptosis of collagen-specific T cells, a reduction in lymphokine production, and suppression of collagen-induced arthritis. The data suggest that this gene therapy regime is a safe and effective method for inhibiting the development of collagen-induced arthritis

In an accompanying commentary in the same issue, George and Maria Tsokos from the Walter Reed Army Institute of Research, Maryland, discuss how the results of Mountz and colleagues propose new possibilities for gene-modified cellbased treatment of rheumatoid arthritis.

TITLE: CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Nov-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, 1 October, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO┬«). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
Cached News: